Argenx Se (ARGX) Total Current Liabilities (2015 - 2026)
Argenx Se (ARGX) posted quarterly Total Current Liabilities of $1.6 billion for Q2 2026, down 99.85% year-on-year from $1041.9 billion in Q2 2025, and up 19.32% on a QoQ basis from $1.3 billion in Q4 2025.
Argenx Se (ARGX) Total Current Liabilities (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Total Current Liabilities for 12 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.
- Quarterly Total Current Liabilities fell 99.85% year-over-year to $1.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (down 99.85% YoY) and the FY2025 annual result came in at $1.3 billion, up 97.04% from the prior year.
- Total Current Liabilities improved to $1.6 billion in Q2 2026 per ARGX's latest filing, from $1.3 billion in the prior quarter.
- Over the last five years, Total Current Liabilities for ARGX reached as high as $1041.9 billion in Q2 2025 and fell as low as $264.6 million in Q2 2022.
- A 5-year average of $116.4 billion and a median of $499.6 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Current Liabilities surged 208435.53% — and 2026, when it plunged 99.85%.
- Year by year, Total Current Liabilities stood at $302.3 million in 2022, then soared by 39.94% to $423.0 million in 2023, then jumped by 58.38% to $669.9 million in 2024, then surged by 97.04% to $1.3 billion in 2025, then grew by 19.32% to $1.6 billion in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $1.6 billion, $1.3 billion, and $1041.9 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 1.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.58 Bn |
| Dec 31, 2025 | 1.32 Bn |
| Jun 30, 2025 | 1,041.90 Bn |
| Dec 31, 2024 | 669.92 Mn |
| Jun 30, 2024 | 499.63 Mn |
| Dec 31, 2023 | 422.99 Mn |
| Jun 30, 2023 | 317.79 Mn |
| Dec 31, 2022 | 302.28 Mn |
| Jun 30, 2022 | 264.60 Mn |
| Dec 31, 2021 | 301.24 Mn |
| Jun 30, 2021 | 244.04 Mn |
| Dec 31, 2020 | 304.63 Mn |
| Jun 30, 2020 | 225.12 Mn |
| Dec 31, 2019 | 182.02 Mn |
| Jun 30, 2019 | 116.51 Mn |
| Dec 31, 2018 | 45.58 Mn |
| Jun 30, 2018 | 39.02 Mn |
| Dec 31, 2017 | 35.38 Mn |
| Jun 30, 2017 | 50.85 Mn |
| Dec 31, 2016 | 46.65 Mn |